{
    "ticker": "LVTX",
    "name": "Lava Therapeutics N.V.",
    "description": "Lava Therapeutics N.V. is an innovative biopharmaceutical company focused on the development of a new class of immunotherapies for cancer treatment. Founded in 2017, Lava Therapeutics is dedicated to harnessing the power of the immune system to fight cancer through its proprietary Gammabody platform, which creates bispecific antibodies that target tumor-associated antigens and engage T cells to enhance anti-tumor activity. The company\u2019s lead product candidates are designed to activate the immune response in a selective manner, aiming to provide more effective and safer treatment options for patients with various types of cancer. Lava Therapeutics is committed to advancing its pipeline and collaborating with partners to bring transformative therapies to patients in need. With a team of experienced scientists and industry professionals, Lava Therapeutics is poised to make significant contributions to the field of oncology and improve patient outcomes through its cutting-edge therapeutic approaches.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Utrecht, Netherlands",
    "founded": "2017",
    "website": "https://www.lavatherapeutics.com",
    "ceo": "Mireille Gillings",
    "social_media": {
        "twitter": "https://twitter.com/LavaTherapeutics",
        "linkedin": "https://www.linkedin.com/company/lava-therapeutics/"
    },
    "investor_relations": "https://www.lavatherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Mireille Gillings",
            "position": "CEO"
        },
        {
            "name": "Mark L. S. K. van de Wetering",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapies",
            "products": [
                "Lava-051",
                "Lava-091"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lava Therapeutics N.V. | Innovative Immunotherapies for Cancer",
        "meta_description": "Discover Lava Therapeutics N.V., a biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment through its proprietary Gammabody platform.",
        "keywords": [
            "Lava Therapeutics",
            "Immunotherapy",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "Gammabody"
        ]
    },
    "faq": [
        {
            "question": "What is Lava Therapeutics known for?",
            "answer": "Lava Therapeutics is known for developing innovative immunotherapies for cancer treatment using its Gammabody platform."
        },
        {
            "question": "Who is the CEO of Lava Therapeutics?",
            "answer": "Mireille Gillings is the CEO of Lava Therapeutics N.V."
        },
        {
            "question": "Where is Lava Therapeutics headquartered?",
            "answer": "Lava Therapeutics is headquartered in Utrecht, Netherlands."
        },
        {
            "question": "What are Lava Therapeutics' main products?",
            "answer": "Lava Therapeutics' main products include Lava-051 and Lava-091, which are focused on cancer immunotherapy."
        },
        {
            "question": "When was Lava Therapeutics founded?",
            "answer": "Lava Therapeutics was founded in 2017."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "REGN",
        "NVS"
    ],
    "related_stocks": [
        "MRNA",
        "PFE",
        "JNJ",
        "GILD"
    ]
}